Yumanity Therapeutics Announces Study Demonstrating In Vivo Efficacy of YTX-7739 in a Glioblastoma Multiforme (GBM) Mouse Model
Retrieved on:
Tuesday, April 6, 2021
YTX-7739 is currently in clinical development by Yumanity Therapeutics as a potential treatment for Parkinsons disease.
Key Points:
- YTX-7739 is currently in clinical development by Yumanity Therapeutics as a potential treatment for Parkinsons disease.
- They had recently shown that GBM cancer stem cells are highly susceptible to pharmacological permutation of stearoyl-CoA desaturase (SCD).
- YTX-7739 is Yumanity Therapeutics proprietary lead small molecule investigational therapy designed to penetrate the blood-brain barrier and inhibit the activity of a novel target, stearoyl-CoA desaturase (SCD).
- Yumanity Therapeutics explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.